Xenetic Biosciences, Inc. Reports Full Year 2023 Financial ResultsAccesswire • about 1 month agoContinued advancement of DNase-based oncology program towards Phase 1 clinical study for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumorsEnded the year with...